Antibiotic Use in Patients with Liver Impairment

General Principles

• The American College of Physicians and other medical societies recommend that for patients with liver impairment, the safest antibiotics include third-generation cephalosporins, piperacillin-tazobactam, and fluoroquinolones with caution, while avoiding or using reduced doses of rifampicin, isoniazid, and macrolides that require hepatic metabolism 1, 2

Antibiotics Requiring Caution

• Rifampicin requires caution in hepatic impairment as noted in clinical guidelines from the Infectious Diseases Society of America 3, 4
• Isoniazid should be used with caution in patients with liver disease due to risk of hepatotoxicity, as recommended by the Centers for Disease Control and Prevention 3
• The European Association for the Study of the Liver recommends that clofazimine, rifabutin, and trimethoprim/sulfamethoxazole should be used with caution in patients with liver impairment 3

Specific Considerations for Different Types of Liver Disease

Acute Liver Failure (ALF)

• The American Association for the Study of Liver Diseases recommends that empirical broad-spectrum antibiotics should be administered to ALF patients if there are signs of sepsis and/or worsening encephalopathy, covering common organisms such as enterobacteria, staphylococcal or streptococcal species 1, 2
• Non-absorbable antibiotics like rifaximin are not recommended to lower ammonia levels in ALF, as stated by the European Society of Intensive Care Medicine 2, 5

Cirrhosis and Acute-on-Chronic Liver Failure (ACLF)

• The European Association for the Study of the Liver recommends that for spontaneous bacterial peritonitis (SBP), cefotaxime has been extensively investigated and covers 95% of flora isolated from ascitic fluid, with a treatment duration of 5 days being as effective as 10-day therapy 6
• The Society of Critical Care Medicine recommends that for upper gastrointestinal bleeding in cirrhotic patients, prophylactic antibiotics (typically third-generation cephalosporins) are recommended to reduce infections, rebleeding, and mortality 7, 8

Antibiotic Selection Based on Infection Type in Liver Disease

Soft Tissue Infections

• The Infectious Diseases Society of America recommends that for community-acquired cellulitis, piperacillin-tazobactam or 3rd generation cephalosporin + oxacillin should be used, while for nosocomial cellulitis, 3rd generation cephalosporin or meropenem + oxacillin/glycopeptides/daptomycin/linezolid should be used 9

Pneumonia

• The American Thoracic Society recommends that for community-acquired pneumonia, piperacillin-tazobactam or ceftriaxone + macrolide or fluoroquinolone should be used, while for nosocomial pneumonia, ceftazidime or meropenem + levofloxacin ± glycopeptides or linezolid should be used 9

Urinary Tract Infections

• The European Association of Urology recommends that for uncomplicated community-acquired UTI, ciprofloxacin or cotrimoxazole should be used, while for UTI with sepsis, 3rd generation cephalosporin or piperacillin-tazobactam should be used 9

Antibiotics to Avoid or Use with Extreme Caution

• Macrolides (erythromycin, clarithromycin) can cause intrahepatic cholestasis and should be used with caution, as recommended by the American Association for the Study of Liver Diseases 10

Common Pitfalls and Caveats

• Cirrhotic patients have increased susceptibility to infections, with bacterial infections documented in 60-80% of patients with ALF, as stated by the American Association for the Study of Liver Diseases 1, 2

Safe Antibiotics for Patients with Liver Injury

First-Line Antibiotic Options

• For community-acquired Spontaneous Bacterial Peritonitis (SBP), third-generation cephalosporins are first-line treatments, as recommended by the European Association for the Study of the Liver 11
• For healthcare-associated or nosocomial SBP, carbapenems alone or combined with daptomycin, vancomycin, or linezolid are recommended if high prevalence of multidrug-resistant organisms, according to the European Association for the Study of the Liver 11

Zosyn Use in Liver Failure

Clinical Indications in Liver Disease

• The European Association for the Study of the Liver recommends piperacillin/tazobactam as an alternative to third-generation cephalosporins for first-line treatment of community-acquired spontaneous bacterial peritonitis (SBP) in cirrhotic patients 12, 13
• The European Association for the Study of the Liver recommends piperacillin/tazobactam as primary therapy for healthcare-associated SBP in low-resistance areas 12, 13

Special Considerations for Critically Ill Patients and Drug Safety

• The European Association for the Study of the Liver notes that piperacillin/tazobactam can precipitate acute encephalopathy in cirrhosis due to decreased renal clearance, increased volume distribution, or increased blood-brain barrier permeability 14
• The European Association for the Study of the Liver advises to avoid amoxicillin/clavulanic acid as an alternative to piperacillin/tazobactam in patients with existing liver disease due to high rates of drug-induced liver injury 13

Alternative Antibiotic Regimens for Critically Ill Patients

Rationale for Antibiotic Selection

• The American Thoracic Society recommends monitoring LFTs every 2-3 days to ensure continued improvement after levofloxacin discontinuation, as levofloxacin can cause acute hepatitis with transaminase elevations, though this is rare 15
• Moxifloxacin should be avoided in patients with liver disease, particularly with transaminases >5x upper limit of normal, making all fluoroquinolones questionable in this setting 15

Recommended Alternative Regimens

• Azithromycin 500mg IV daily provides excellent atypical coverage, including Legionella, Mycoplasma, and Chlamydia, and can be used in patients with liver impairment, though requires caution 16, 17
• The European Respiratory Society recommends piperacillin-tazobactam for broad gram-negative coverage, including Pseudomonas aeruginosa, which is considered safe in liver disease and is specifically recommended for critically ill patients with liver impairment 17, 18

Alternative Options

• Doxycycline 100mg IV/PO twice daily provides atypical coverage and is generally safe in liver disease, effective against respiratory pathogens 16, 17

Critical Monitoring Considerations

• The American Association for the Study of Liver Diseases recommends monitoring LFTs every 2-3 days to ensure continued improvement after levofloxacin discontinuation 15

When to Escalate Coverage

• The European Respiratory Society recommends adding an aminoglycoside, such as gentamicin or amikacin, to piperacillin-tazobactam for enhanced gram-negative coverage in patients with septic shock, as dual pseudomonal coverage is recommended in this scenario 17